MA28032A1 - Utilisation de cyclosporines modifiees pour le traitement de troubles lies au vhc - Google Patents

Utilisation de cyclosporines modifiees pour le traitement de troubles lies au vhc

Info

Publication number
MA28032A1
MA28032A1 MA28865A MA28865A MA28032A1 MA 28032 A1 MA28032 A1 MA 28032A1 MA 28865 A MA28865 A MA 28865A MA 28865 A MA28865 A MA 28865A MA 28032 A1 MA28032 A1 MA 28032A1
Authority
MA
Morocco
Prior art keywords
treatment
related disorders
cyclosporins
hcv related
modified cyclosporins
Prior art date
Application number
MA28865A
Other languages
English (en)
Inventor
Makoto Hijikata
Kunitada Shimotohno
Koichi Watashi
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA28032A1 publication Critical patent/MA28032A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Cette invention concerne ses cyclosporines sans activité immunosuppressive se liant à la cyclophiline (voir formules I, Ia ou II) comme définies dans le descriptif, qui possèdent des propriétés puissantes dans la prévention ou le traitement des infections par le virus de l'hépatite C.
MA28865A 2003-09-03 2006-03-10 Utilisation de cyclosporines modifiees pour le traitement de troubles lies au vhc MA28032A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0320638.0A GB0320638D0 (en) 2003-09-03 2003-09-03 Organic compounds

Publications (1)

Publication Number Publication Date
MA28032A1 true MA28032A1 (fr) 2006-07-03

Family

ID=28686843

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28865A MA28032A1 (fr) 2003-09-03 2006-03-10 Utilisation de cyclosporines modifiees pour le traitement de troubles lies au vhc

Country Status (29)

Country Link
US (1) US7968518B2 (fr)
EP (2) EP1797892B1 (fr)
JP (1) JP4688806B2 (fr)
KR (1) KR101116968B1 (fr)
CN (1) CN1842343A (fr)
AU (2) AU2004268382A1 (fr)
BR (1) BRPI0414062B8 (fr)
CA (1) CA2537137C (fr)
CY (1) CY1110506T1 (fr)
DE (1) DE602004022061D1 (fr)
DK (1) DK1663287T3 (fr)
ES (1) ES2328361T3 (fr)
GB (1) GB0320638D0 (fr)
HR (1) HRP20090535T1 (fr)
IL (1) IL173909A (fr)
IS (1) IS2917B (fr)
MA (1) MA28032A1 (fr)
MX (1) MXPA06002394A (fr)
NO (1) NO20061479L (fr)
NZ (1) NZ545495A (fr)
PL (1) PL1663287T3 (fr)
PT (1) PT1663287E (fr)
RU (1) RU2389501C2 (fr)
SG (1) SG149063A1 (fr)
SI (1) SI1663287T1 (fr)
TN (1) TNSN06071A1 (fr)
TW (1) TWI342782B (fr)
WO (1) WO2005021028A1 (fr)
ZA (1) ZA200601550B (fr)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1091975E (pt) 1998-07-01 2006-05-31 Debiopharm Sa Nova ciclosporina com um perfil de actividade melhorado
CA2518265A1 (fr) 2003-03-17 2004-09-30 Albany Molecular Research, Inc. Nouvelles cyclosporines
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
GB0500020D0 (en) * 2005-01-04 2005-02-09 Novartis Ag Organic compounds
BRPI0513370A (pt) 2004-07-14 2008-05-06 Novartis Ag uso de uma combinação de ciclosporina e interferonas peguilados para tratamento de hepatite c (hcv)
JP2008514702A (ja) 2004-09-29 2008-05-08 エーエムアール テクノロジー インコーポレイテッド 新規シクロスポリン類似体およびそれらの薬学的使用
US7378391B2 (en) 2004-09-29 2008-05-27 Amr Technology, Inc. Cyclosporin alkyne analogues and their pharmaceutical uses
US7196161B2 (en) 2004-10-01 2007-03-27 Scynexis Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
ATE490778T1 (de) * 2004-10-01 2010-12-15 Debiopharm Sa Verwendung von äd-mealaü3-äetvalü4-ciclosporin zur behandlung von hepatitis-c-infektion
PT1802650E (pt) * 2004-10-01 2011-12-30 Scynexis Inc Derivados da ciclosporina 3-éter e 3-tioéter substituída para o tratamento e prevenção da infecção de hepatite c
WO2006041631A2 (fr) 2004-10-06 2006-04-20 Amr Technology, Inc. Alcynes de cyclosporine, et leur utilite comme agents pharmaceutiques
ES2314731T3 (es) 2004-11-22 2009-03-16 Astellas Pharma Inc. Analogo de ciclosporina.
WO2006071619A1 (fr) 2004-12-23 2006-07-06 Novartis Ag Compositions pour le traitement du vhc
NZ555142A (en) * 2004-12-23 2010-03-26 Novartis Ag Compounds for flaviviridae treatment
RU2427372C2 (ru) 2005-06-17 2011-08-27 Новартис Аг Применение санглиферина для лечения вируса гепатита с
WO2007041632A2 (fr) * 2005-09-30 2007-04-12 Scynexis, Inc. Procedes et compositions pharmaceutiques pour traiter et prevenir une infection par le virus de l'hepatite c
CN101316606B (zh) * 2005-09-30 2015-05-27 西尼克斯公司 治疗和预防丙型肝炎感染的方法和药物组合物
WO2007041631A1 (fr) * 2005-09-30 2007-04-12 Scynexis, Inc. Derives d'arylalkyle et d'heteroarylalkyle de cyclosporine a utilises pour traiter et prevenir une infection virale
KR101273681B1 (ko) 2005-10-26 2013-06-25 아스텔라스세이야쿠 가부시키가이샤 신규 시클릭 펩티드 화합물
US7696166B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
US7696165B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
CA2652662C (fr) 2006-05-19 2015-11-03 Scynexis, Inc. Procede de traitement et de prevention de troubles oculaires
KR101089112B1 (ko) * 2006-06-02 2011-12-06 피씨 제스띠옹 에스.아.에스. 활성 전자 관리
KR20090083902A (ko) * 2006-10-12 2009-08-04 노파르티스 아게 개질된 사이클로스포린의 용도
WO2008069917A2 (fr) * 2006-11-20 2008-06-12 Scynexis, Inc. Nouveaux peptides cycliques
CN101616683A (zh) 2007-01-04 2009-12-30 德比奥法姆股份有限公司 用于治疗Ullrich先天性肌营养不良的非免疫抑制性环孢霉素
EP2150269B1 (fr) * 2007-05-02 2012-11-21 Astellas Pharma Inc. Nouveaux composés peptidiques cycliques
EP2193807A4 (fr) * 2007-08-24 2012-09-12 Univ Sapporo Medical Protéine de liaison à la cyclosporine a
US20090306033A1 (en) * 2008-06-06 2009-12-10 Keqiang Li Novel cyclic peptides
JP5820722B2 (ja) * 2008-06-06 2015-11-24 スシネキス インク シクロスポリン類似体及びｈｃｖ感染の治療におけるその使用
MX2011001152A (es) * 2008-07-30 2011-06-09 Isotechnika Pharma Inc Moleculas de analogo de ciclosporina no-inmunesupresoras.
MX2011003259A (es) * 2008-09-24 2011-04-21 Astellas Pharma Inc Compuesto de peptido y metodo para producir el mismo.
CN102202679B (zh) 2008-11-06 2014-05-07 帝柏奥研究制药有限公司 环十一缩酚酸肽化合物及其作为药物的用途
US8536114B2 (en) * 2008-12-31 2013-09-17 Scynexis, Inc. Macrocycles
RU2492181C2 (ru) * 2009-01-30 2013-09-10 Энанта Фармасьютикалс, Инк. Аналоги циклоспорина для предупреждения или лечения инфекции гепатита с
US8481483B2 (en) 2009-02-19 2013-07-09 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8349312B2 (en) 2009-07-09 2013-01-08 Enanta Pharmaceuticals, Inc. Proline substituted cyclosporin analogues
US8367053B2 (en) 2009-07-09 2013-02-05 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8685917B2 (en) 2009-07-09 2014-04-01 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
WO2011063076A1 (fr) 2009-11-19 2011-05-26 Itherx Pharmaceuticals, Inc. Méthodes de traitement du virus de l'hépatite c avec des composés d'oxo-acétamide
CN102869367A (zh) 2009-12-09 2013-01-09 西尼克斯公司 新颖的环肽
US8623814B2 (en) 2010-02-23 2014-01-07 Enanta Pharmaceuticals, Inc. Antiviral agents
WO2012045704A1 (fr) 2010-10-05 2012-04-12 Novartis Ag Nouveaux traitements d'une infection par le virus de l'hépatite c
RU2013129824A (ru) 2010-11-30 2015-01-10 Новартис Аг Новое лечение инфекции вируса гепатита с
JO3337B1 (ar) 2010-12-13 2019-03-13 Debiopharm Sa تركيبات صيدلية تشمل أليسبوريفير
AU2011342284C1 (en) 2010-12-15 2017-07-13 Contravir Pharmaceuticals, Inc. Cyclosporine analogue molecules modified at amino acid 1 and 3
KR20140007927A (ko) 2011-03-31 2014-01-20 노파르티스 아게 C형 간염 바이러스 감염을 치료하기 위한 알리스포리비르
WO2012131061A1 (fr) 2011-04-01 2012-10-04 Novartis Ag Traitement destiné à une infection par le virus de l'hépatite b seul ou en combinaison avec le virus de l'hépatite delta et à des maladies hépatiques associées
RU2013150344A (ru) 2011-04-13 2015-05-20 Новартис Аг Лечение инфекции вируса гепатита алисповиром
US20140228281A1 (en) 2011-09-27 2014-08-14 Novartis Ag Alisporivr for treatment of hepatitis c virus infection
WO2013169616A1 (fr) 2012-05-07 2013-11-14 Novartis Ag Modulation pharmacocinétique par de l'alisporivir
WO2013181339A2 (fr) 2012-06-01 2013-12-05 Allergan, Inc. Analogues de cyclosporine a
US8906853B2 (en) 2012-11-28 2014-12-09 Enanta Pharmaceuticals, Inc. [N-Me-4-hydroxyleucine]-9-cyclosporin analogues for treatment and prevention of hepatitis C infection
WO2015008223A1 (fr) 2013-07-17 2015-01-22 Novartis Ag Traitement du virus de l'hépatite c avec l'alisporivir et la ribavirine
HK1223843A1 (zh) 2013-08-26 2017-08-11 Enanta Pharmaceuticals, Inc. 用於預防或治療丙型肝炎的環孢菌素類似物
WO2015136455A1 (fr) 2014-03-13 2015-09-17 Novartis Ag Nouveaux traitements d'une infection par le virus de l'hépatite c
US9669095B2 (en) 2014-11-03 2017-06-06 Enanta Pharmaceuticals, Inc. Cyclosporin analogues for preventing or treating hepatitis C infection
TW201639873A (zh) 2015-01-08 2016-11-16 歐樂根公司 Ｍｅｂｍｔ側鏈已環化之環孢菌素衍生物
US20230330132A1 (en) * 2020-08-24 2023-10-19 Nanomerics Limited Viral inhibitors
WO2026119137A1 (fr) * 2024-12-03 2026-06-11 Farsight Medical Technology (Shanghai) Co., Ltd. Analogues de cyclosporine et utilisations dans des thérapies contre l'hépatite b

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639724A (en) * 1984-07-24 1997-06-17 Sandoz Ltd. Cyclosporin galenic forms
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
JP2514950B2 (ja) 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
GB2222770B (en) 1988-09-16 1992-07-29 Sandoz Ltd Pharmaceutical compositions containing cyclosporins
FI111730B (fi) * 1990-11-02 2003-09-15 Novartis Ag Menetelmä ei-immunosuppressiivisen syklosporiinin valmistamiseksi
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US6174868B1 (en) * 1992-09-10 2001-01-16 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of hepatitis C virus-associated diseases
KR0155015B1 (ko) 1992-10-21 1998-12-01 고우야 마사시 2-아미노-1,3-프로판디올 화합물 및 면역 억제제
HUT75533A (en) 1993-11-10 1997-05-28 Schering Corp Improved interferon polymer conjugates
DE69524962T4 (de) 1994-08-22 2003-08-28 Mitsubishi Pharma Corp., Osaka Benzolderivate und deren medizinische verwendung
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
JP3786447B2 (ja) * 1995-03-31 2006-06-14 エーザイ株式会社 Ｃ型肝炎の予防・治療剤
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
FR2757521B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2757522B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2757520B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derive de cyclosporine, sa preparation et les compositions pharmaceutiques qui le contiennent
ES2240868T3 (es) 1997-04-04 2005-10-16 Mitsubishi Pharma Corporation Compuesto de 2-aminopropano -1,3-diol, su uso farmaceutico e intermedios en su sintesis.
JPH1180026A (ja) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
GB9811854D0 (en) * 1998-06-02 1998-07-29 Ciba Geigy Ag Organic compounds
PT1091975E (pt) 1998-07-01 2006-05-31 Debiopharm Sa Nova ciclosporina com um perfil de actividade melhorado
CZ200350A3 (cs) 2000-07-13 2003-05-14 Sankyo Company Limited Aminoalkoholové deriváty
WO2002018395A1 (fr) 2000-08-31 2002-03-07 Merck & Co., Inc. Derives de phosphates utilises en tant qu'agents immuno-regulateurs
CA2426381A1 (fr) * 2000-10-19 2002-04-25 Fujisawa Pharmaceutical Co., Ltd. Inhibiteur de degat cellulaire
JP2002125683A (ja) * 2000-10-27 2002-05-08 Tokyoto Igaku Kenkyu Kiko インターフェロンの有効性を予測する方法並びにそれに用いられるプライマー及びプローブ
MXPA03008755A (es) 2001-03-26 2004-02-18 Novartis Ag Derivados de 2-amino-propanol.
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
KR100913269B1 (ko) 2001-09-27 2009-08-21 교린 세이야꾸 가부시키 가이샤 디아릴 황화물 유도체, 그의 염 및 이를 이용한 면역억제제
JP4152884B2 (ja) 2001-09-27 2008-09-17 杏林製薬株式会社 ジアリールエーテル誘導体とその付加塩及び免疫抑制剤
ATE448193T1 (de) 2002-01-18 2009-11-15 Merck & Co Inc ßN-(BENZYL)AMINOALKYL CARBOXYLATE, PHOSPHINATE, PHOSPHONATE UND TETRAZOLE ALS EDG REZEPTORAGONISTENß
DE60329073D1 (de) 2002-01-18 2009-10-15 Merck & Co Inc Edg-rezeptoragonisten
US20030213603A1 (en) 2002-05-14 2003-11-20 Fisher David B. Dual use extension apparatus for a tool
KR20050035194A (ko) 2002-06-28 2005-04-15 이데닉스 (케이만) 리미티드 플라비비리다에 감염 치료용 2'-ｃ-메틸-3'-ｏ-ｌ-발린에스테르 리보푸라노실 사이티딘
GB0313444D0 (en) 2003-06-11 2003-07-16 Midland Medical Technologies L Modular dysplasia cup
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
ATE490778T1 (de) 2004-10-01 2010-12-15 Debiopharm Sa Verwendung von äd-mealaü3-äetvalü4-ciclosporin zur behandlung von hepatitis-c-infektion
WO2006071619A1 (fr) 2004-12-23 2006-07-06 Novartis Ag Compositions pour le traitement du vhc

Also Published As

Publication number Publication date
PT1663287E (pt) 2009-09-03
NO20061479L (no) 2006-06-02
KR20060132798A (ko) 2006-12-22
DE602004022061D1 (de) 2009-08-27
CA2537137A1 (fr) 2005-03-10
NZ545495A (en) 2010-01-29
TW200524626A (en) 2005-08-01
JP2007504260A (ja) 2007-03-01
EP1797892B1 (fr) 2013-10-23
US20070275884A1 (en) 2007-11-29
RU2006110533A (ru) 2007-10-10
CY1110506T1 (el) 2015-04-29
RU2389501C2 (ru) 2010-05-20
AU2004268382A1 (en) 2005-03-10
EP1663287A1 (fr) 2006-06-07
AU2008203031A1 (en) 2008-07-31
BRPI0414062B8 (pt) 2021-05-25
IL173909A0 (en) 2006-07-05
SI1663287T1 (sl) 2009-10-31
ZA200601550B (en) 2007-05-30
WO2005021028A1 (fr) 2005-03-10
EP1797892A1 (fr) 2007-06-20
CA2537137C (fr) 2013-05-28
MXPA06002394A (es) 2006-06-20
EP1663287B1 (fr) 2009-07-15
JP4688806B2 (ja) 2011-05-25
US7968518B2 (en) 2011-06-28
AU2008203031B2 (en) 2011-04-07
SG149063A1 (en) 2009-01-29
CN1842343A (zh) 2006-10-04
DK1663287T3 (da) 2009-11-09
GB0320638D0 (en) 2003-10-01
HRP20090535T1 (hr) 2009-11-30
HK1091732A1 (en) 2007-01-26
IS8371A (is) 2006-03-24
PL1663287T3 (pl) 2009-12-31
KR101116968B1 (ko) 2012-03-14
IL173909A (en) 2011-03-31
ES2328361T3 (es) 2009-11-12
TNSN06071A1 (en) 2007-10-03
BRPI0414062B1 (pt) 2019-06-25
IS2917B (is) 2014-12-15
TWI342782B (en) 2011-06-01
BRPI0414062A (pt) 2006-10-24

Similar Documents

Publication Publication Date Title
MA29757B1 (fr) Peptides macrocycliques en tant qu'inhibiteurs de la protease ns3 du vhc
MA30198B1 (fr) Inhibiteurs de la protease ns3 du vhc
TNSN06071A1 (en) Use of modified cyclosporins for the treatment of hcv disorders
BR0008688A (pt) Antagonistas de il-18 recombinantes utilizáveis no tratamento de distúrbios mediados por il-18
EP1390029A4 (fr) Phenylindoles pour le traitement de l'infection par le vih
BR0114390A (pt) éteres de 7-desmetilrapamicina
MA28950B1 (fr) Utilisation de cyclosporine dans le traitement d'infections a hepatite c et composition pharmaceutique contenant ladite cyclosporine
EP1838321A4 (fr) Antagonistes de cxcr4 pour le traitement de l'infection due au vih
MA26221A1 (fr) Nouveaux preconcentres de microemulsion d'analogue de la cyclosporine.
TNSN07066A1 (fr) Inhibiteurs de l'arn-polymerase, dependant d'arn, du virus de l'hepatite c, et compositions et traitements les utilisant
WO2005032471A3 (fr) Inhibiteurs de type benzylether et benzylamino de beta-secretase pour le traitement de la maladie d'alzheimer
BR0211986A (pt) 29-enóis de rapamicina
DE602004026053D1 (fr)
MA30250B1 (fr) Vaccins destines a lutter contre une infection a chlamydia
RU2012120343A (ru) Морфогенные белки кости (bmp), рецепторы вмр и связывающие вмр белки и их применение для диагностики и лечения глаукомы
EP2039699A3 (fr) Procédés d'extraction pour purifier le sucralose
ATE360031T1 (de) Chimäre proteine und anwendungen
WO2002028866A3 (fr) Hydroxyesters de 7-desmethylrapamycine
EP1753777A4 (fr) METHODES ET COMPOSITIONS POUR LE TRAITEMENT ET LA PREVENTION D'UNE INFECTION PAR LE VIH AU MOYEN DE TRIM5a
ATE296108T1 (de) Cyanovirin konjugate, matrix-verankertes cyanovirin und anti-cyanovirin antikörper, und verwandte zusammensetzungen und anwendungen
MA28038A1 (fr) Thienopyrazoles
ATE335499T1 (de) Zusammensetzungen zur behandlung von staphylococcus aureus infektionen
MA30865B1 (fr) Utilisation de cyclosporines modifiees
EP1664011A4 (fr) Compositions ophtalmiques pour le traitement de l'hypertension oculaire
EP2322206A3 (fr) Nétrine 1 mutée, ses fragments et leur utilisation comme médicaments